Cozzi Emanuele
Transpl Immunol. 2009 Jun;21(2):57-9. doi: 10.1016/j.trim.2009.05.002. Epub 2009 May 14.
In recent years the development of novel immunosuppressive strategies and new lines of engineered pigs have enabled improved xenograft survival in the clinically-relevant pig-to-primate models (especially in islet xenotransplantation). Furthermore, researchers have now developed appropriate biomolecular tools to address rapidly the remaining barriers and render organs from source pigs more "compatible" with man. Efficacy has been the main focus of the research conducted in the last few years. However, other fundamental issues, such as those regarding the physiology, the safety, the ethics and regulatory aspects of xenotransplantation, will need to be addressed satisfactorily prior to proceeding with clinical xenotransplantation trials.
近年来，新型免疫抑制策略的发展以及新型工程猪品系的出现，使得在临床相关的猪到灵长类动物模型中（尤其是胰岛异种移植）异种移植物的存活情况得到了改善。此外，研究人员现已开发出合适的生物分子工具，以迅速解决剩余的障碍，并使供体猪的器官与人类更“兼容”。疗效一直是过去几年研究的主要重点。然而，在进行临床异种移植试验之前，还需要令人满意地解决其他一些基本问题，例如异种移植的生理学、安全性、伦理和监管方面的问题。
